Latest Pharma Insights
Financing Quarterly Statistics, Q2 2026
During Q2, biopharmas brought in an aggregate $42.5bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.6bn.
In Vivo - September 8, 2026
During Q2, biopharmas brought in an aggregate $42.5bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.6bn.
In Vivo - September 8, 2026
If Alexa Won’t Recommend You, ‘You’re Invisible’: How Amazon’s New AI Tool Is Shaking Up OTC
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Get To Know: Indian Wellness Tech Licensing Specialist Boudhik Ventures
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Novartis M&A Strategy Under Spotlight After Another Phase III Blow
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,’ analysts at Jefferies have claimed.
Scrip - September 8, 2026
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,’ analysts at Jefferies have claimed.
Scrip - September 8, 2026
Stock Watch: mRNA’s Cancer Win Puts The Antivax Lobby In a Corner
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR vaccine. But the mRNA vaccine platform demonized by the administration has now posted positive Phase III results in melanoma.
Scrip - September 8, 2026
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR vaccine. But the mRNA vaccine platform demonized by the administration has now posted positive Phase III results in melanoma.
Scrip - September 8, 2026
Fresenius Kabi Latest To Launch Generic Bridion As Merck Prepares US Market Exit
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Biocon Locks In 10-Year Pertuzumab Opportunity In Brazil
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
Oncology Trial Waivers In India: Big Pharma, Local Firms Navigate Path To Faster Entry
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
Scrip - September 8, 2026
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
Scrip - September 8, 2026
‘It’s Time To Put The Muttering To Rest’ – Samsung Bioepis Rebuts Biosimilar Drift Concerns
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
BrainChild Launches With $116m To Test CAR-T In Pediatric Brain Cancer
BrainChild came out of stealth with $116m in series A cash and CAR-T programs for delivery to the central nervous system, starting with diffuse intrinsic pontine glioma (DIPG).
Scrip - September 8, 2026
BrainChild came out of stealth with $116m in series A cash and CAR-T programs for delivery to the central nervous system, starting with diffuse intrinsic pontine glioma (DIPG).
Scrip - September 8, 2026
Accord Pins Denosumab Launch Delay On Q-Code Timing
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Scrip - September 8, 2026
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Scrip - September 8, 2026
Strategic Intent: Evolving Requirements Of Life Sciences Leadership
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
In Vivo - September 8, 2026
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
In Vivo - September 8, 2026
Novartis Stock Sinks 10% As Del-Desiran Flops In Phase III
It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.
Scrip - September 8, 2026
It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.
Scrip - September 8, 2026
iRhythm To Buy VitalConnect, Plugging 30-Day MCT Gap And Broadening Its Cardiac Monitoring Platform
The $287.5m VitalConnect deal buys iRhythm 20–30% of the mobile cardiac telemetry market that Zio AT cannot serve and leapfrogs its own pre-clearance MCT device. CEO Quentin Blackford said its internal development program will still continue.
Medtech Insight - September 8, 2026
The $287.5m VitalConnect deal buys iRhythm 20–30% of the mobile cardiac telemetry market that Zio AT cannot serve and leapfrogs its own pre-clearance MCT device. CEO Quentin Blackford said its internal development program will still continue.
Medtech Insight - September 8, 2026
Novartis M&A Strategy Under Spotlight After Another Phase III Blow
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,’ analysts at Jefferies have claimed.
Scrip - September 8, 2026
The late-stage failures within days of pelacarsen and del-desiran ‘will likely raise questions again about Novartis's due diligence and BD approach,’ analysts at Jefferies have claimed.
Scrip - September 8, 2026
Stock Watch: mRNA’s Cancer Win Puts The Antivax Lobby In a Corner
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR vaccine. But the mRNA vaccine platform demonized by the administration has now posted positive Phase III results in melanoma.
Scrip - September 8, 2026
Weak Q2 vaccine sales across big pharma coincided with rising US antivax sentiment and a presidential order to split the MMR vaccine. But the mRNA vaccine platform demonized by the administration has now posted positive Phase III results in melanoma.
Scrip - September 8, 2026
Oncology Trial Waivers In India: Big Pharma, Local Firms Navigate Path To Faster Entry
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
Scrip - September 8, 2026
India's Phase III trial waiver route is gaining traction as foreign and local firms pursue the pathway for oncology drugs even as the regulator continues to draw firm lines on Indian population safety data.
Scrip - September 8, 2026
BrainChild Launches With $116m To Test CAR-T In Pediatric Brain Cancer
BrainChild came out of stealth with $116m in series A cash and CAR-T programs for delivery to the central nervous system, starting with diffuse intrinsic pontine glioma (DIPG).
Scrip - September 8, 2026
BrainChild came out of stealth with $116m in series A cash and CAR-T programs for delivery to the central nervous system, starting with diffuse intrinsic pontine glioma (DIPG).
Scrip - September 8, 2026
Roivant’s Mosliciguat Heads To Phase III After 56% PVR Reduction In PH-ILD
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Scrip - September 8, 2026
The company’s PVR win sets the stage for mosliciguat’s Phase III test, with the company now eyeing a bigger role in PH-ILD.
Scrip - September 8, 2026
Novartis Stock Sinks 10% As Del-Desiran Flops In Phase III
It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.
Scrip - September 8, 2026
It is the second major clinical setback in a week for the Swiss firm after pelacarsen disappointed in a Phase III cardiovascular outcomes study.
Scrip - September 8, 2026
iRhythm To Buy VitalConnect, Plugging 30-Day MCT Gap And Broadening Its Cardiac Monitoring Platform
The $287.5m VitalConnect deal buys iRhythm 20–30% of the mobile cardiac telemetry market that Zio AT cannot serve and leapfrogs its own pre-clearance MCT device. CEO Quentin Blackford said its internal development program will still continue.
Medtech Insight - September 8, 2026
The $287.5m VitalConnect deal buys iRhythm 20–30% of the mobile cardiac telemetry market that Zio AT cannot serve and leapfrogs its own pre-clearance MCT device. CEO Quentin Blackford said its internal development program will still continue.
Medtech Insight - September 8, 2026
If Alexa Won’t Recommend You, ‘You’re Invisible’: How Amazon’s New AI Tool Is Shaking Up OTC
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Amazon's integration of AI into its shopping experience is set to fundamentally alter how consumers discover and choose consumer health products. Ross Barber of World Products argues that brands competing only for search rankings are already playing yesterday's game.
HBW Insight - September 8, 2026
Get To Know: Indian Wellness Tech Licensing Specialist Boudhik Ventures
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Q&A with Boudhik Ventures director Ishan Tiwari on the Indian firm's mandate-driven model and its push to license Renavita, a patented kidney wellness formulation, in the UK and Europe.
HBW Insight - September 8, 2026
Fresenius Kabi Latest To Launch Generic Bridion As Merck Prepares US Market Exit
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Fresenius Kabi has launched a pre-filled syringe generic sugammadex in the US, as growing generic competition drives Merck to anticipate discontinuing US Bridion sales.
Generics Bulletin - September 8, 2026
Biocon Locks In 10-Year Pertuzumab Opportunity In Brazil
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
Biocon has secured a 10-year route into Brazil’s public pertuzumab market through a Productive Development Partnership program that combines exclusive access with phased localization and technology transfer for the Perjeta biosimilar.
Generics Bulletin - September 8, 2026
‘It’s Time To Put The Muttering To Rest’ – Samsung Bioepis Rebuts Biosimilar Drift Concerns
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
Following the publication of their co-authored journal article on why product drift is not an issue for biosimilars, Samsung Bioepis executives Gillian Woollett and Joseph Park explain why they felt the longstanding issue needed to be put to rest.
Generics Bulletin - September 8, 2026
Accord Pins Denosumab Launch Delay On Q-Code Timing
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
Accord says securing a Q-code was the decisive factor behind the delayed US launch of Osvyrti and Jubereq, which reached the market around nine months after a legal sales restriction expired.
Generics Bulletin - September 8, 2026
Financing Quarterly Statistics, Q2 2026
During Q2, biopharmas brought in an aggregate $42.5bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.6bn.
In Vivo - September 8, 2026
During Q2, biopharmas brought in an aggregate $42.5bn in financing and device company fundraising totaled $3bn; while in vitro diagnostic firms and research tools players raised $1.6bn.
In Vivo - September 8, 2026
Strategic Intent: Evolving Requirements Of Life Sciences Leadership
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
In Vivo - September 8, 2026
In this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the life sciences and biotech industries, reflecting on inflection points for hiring practices and emerging structural trends.
In Vivo - September 8, 2026